30/07/2016 23:37:53 Cookie Policy +44 (0) 207 0700 961 Free Membership Login
Share Name Share Symbol Market Type Share ISIN Share Description
Alliance Pharma LSE:APH London Ordinary Share GB0031030819 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.50p -1.08% 45.75p 45.75p 46.25p 46.25p 45.25p 45.25p 519,549 16:16:51
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 48.3 15.2 4.7 9.8 214.27

Alliance Pharma Share Discussion Threads

Showing 1326 to 1349 of 1350 messages
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
DateSubjectAuthorDiscuss
30/7/2016
00:08
IG have increased the initial margin on APH from 25% to 50% today , I can't see any bad news in the media, am I missing something ? dodgy AIM oilers have less of a margin than that.
pollnagorm
21/7/2016
11:53
I haven't seen the Hardman report gamwah, so thanks for posting it. Well worth a read for anybody considering investing here.
2vdm
19/7/2016
13:13
Been looking at this for a while, I have gone in today. I found this doc from April, here is a link if interested not sure if its been posted before.... hxxp://www.hardmanandco.com/docs/default-source/company-docs/alliance-pharma-documents/28-04-16-managing-a-period-of-change
gamwah
19/7/2016
12:16
Large descending triangle consolidation. Market reaction could unleash some momentum. Given the results, you would think its to the upside.
petethehippy
19/7/2016
09:16
Good RNS. APH seems to have absorbed Sinclair well and we will know more when results finalised/published. Nice staedy compamy with mngt appearing to know what they are doing. Glad to hear that the Brexit vote unlikely to have negative impact on sales. Have topped up as I think this will reward us in the long run
2vdm
19/7/2016
08:19
Steady progress
pollnagorm
06/7/2016
10:09
Interesting - just looked at the annual report and in particular page 6: Following the Sinclair acquisition, we now have a substantially larger international footprint. Previously, we made approximately 80% of our sales in the UK. Now, the split is broadly 50% UK, 25% Western Europe excluding UK, and 25% Rest of World. Should already/soon be benefiting from the falling pound.
corbeta
25/6/2016
11:29
mazarin> BUT a large part of the growth plan was based on expansion into ~Europe. (from memory) so I would expect strong headwinds in this area. Could be that hhey were blue yeaterday as part of the general pharma resilence - GSK was a big (relativly) winner as were AZN and Shire.
pugugly
25/6/2016
08:27
APH, yesterday's "lone Riser" amidst a sea of red.
mazarin
03/6/2016
11:48
Nice article in the Investors Chronicle this week. Double bottom on the chart. Solid business. Waiting for momentum.
petethehippy
25/5/2016
11:11
Nice solid announcement at the AGM this a.m.- "The year has started well. The Alliance business and the recently acquired Sinclair Healthcare Products business together generated revenues of GBP30.5 million for the first four months of 2016, which is in line with the Board's expectations. "Kelo-Cote(TM), our scar reduction product from the Sinclair portfolio, is now our largest-selling brand. Its sales of GBP3.0 million in the first four months of 2016 were in line with forecast. Hydromol(TM), the largest selling brand in the Alliance product range, continued to grow well with sales in the first four months of the year up 7% on the same period in the prior year. The UK consumer healthcare business also continues to develop well, with sales of GBP2.9 million up 20% on the same period last year, driven by strong growth of Ashton and Parsons(TM) and Macushield(TM), which was acquired in February 2015. "The key activity of combining the two organisations is underway. We are in the process of integrating the Sinclair products under the Alliance name and of aligning the operational capabilities of the enlarged company; both projects are progressing to plan. "We look forward to the year ahead with confidence." Roll on more news.
2vdm
25/5/2016
08:06
Good steady rise at the moment
jamdan1
20/5/2016
18:46
Robbie Burns (NT) has bought back in this week giving it a bit of publicity on his blog
mrblonde77
28/4/2016
07:58
Agree. It's important as the company is now carrying significant loan 70m, o profit/debt ratio/gearing important
2vdm
08/4/2016
07:22
I will wait to see how this Sinclair acquisition is absorbed into the business before adding to my existing holding.
capercaillie
07/4/2016
16:12
Maz I just think investors are impatient. Cash flow has reduced due to acquisition, debt levels were known about and lypsyl / Ashton and Parsons income was relatively small beer anyway. That said, you are correct - Mr Market doesn't like it but no need to listen to Mr Market anyway. Personally a core holding for me - given time will be a significant business. I will look to continue to add based on any valuation anomalies over the next 12 months. All the best
norbert colon
07/4/2016
15:53
Clearly there are some who are disappointed with elements contained in today's results. Possibly ".....2015 free cash flow reduced to GBP6.3m (2014: GBP10.3m)", an increase in debt incurred to finance Sinclair acquisition and lower than anticipated sales of Kelo-stretch(TM) that was expected to be a key growth brand, despite extensive promotional activities....? The overriding message, however, is promising with a 10% increase of dividend and profitability.
mazarin
07/4/2016
14:56
Video interview with John Dawson http://tinyurl.com/h3bh6at John Dawson, chief executive of Alliance Pharma PLC (LON:APH), tells Proactive Investors that the recent acquisition of the Sinclair Healthcare Products Business has had a “transformational” effect on the business. He says the deal doubles Alliance’s sales, profits, and market capitalisation, adding that the company is now “in a place that we can bid for other opportunities in the future”. Dawson goes on to say it also gives the company a “much stronger presence across the top five EU countries,” as well as in China and South East Asia. Alliance reported robust final statement for the year ended 31 December 2015 on Thursday, with revenue up 11% to £48.3mln, compared to £43.5mln the previous year.
proactivest
03/3/2016
12:32
Hardman research report issued this morning looks good, although I do not see a revised target price. I've now added some more.
webclick99
28/1/2016
10:22
Encouraging to see those large buys going through this morning!
the explorer
27/1/2016
10:20
Had a little 'nibble' this morning..if it's good enough for Slater..... An article looking at 3 small caps held by Mark Slater, including APH Https://uk.finance.yahoo.com/news/3-promising-mark-slater-picks-093002215.html
gymratt
16/1/2016
00:49
Hi guys, another holder, quietly watching and seeing events unfold. Excellent week. Stake building continues. Not very liquid stock and the trend looking good too! :0) All the best.
the_analyst
15/1/2016
14:37
Still one of my bigger holdings. Strength noted over recent days.
norbert colon
15/1/2016
14:14
Yup Pimpernel4.....they're 49p (fraction over now) bid in big size. Always interesting when the general mkt is getting smashed and it doesn't put the buyer(s) off. Bodes well...
roper
Chat Pages: 54  53  52  51  50  49  48  47  46  45  44  43  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20160730 22:37:53